XML 157 R100.htm IDEA: XBRL DOCUMENT v3.25.0.1
Principal changes in the scope of consolidation in 2022 and 2021 - Additional Information (Details)
€ / shares in Units, $ / shares in Units, € in Millions, $ in Millions
 1 Months Ended 8 Months Ended 11 Months Ended 12 Months Ended
Nov. 29, 2024
EUR (€)
Nov. 29, 2024
USD ($)
Sep. 29, 2023
EUR (€)
Jun. 17, 2022
EUR (€)
May 10, 2022
EUR (€)
€ / shares
shares
May 03, 2022
Mar. 17, 2022
EUR (€)
Nov. 30, 2022
EUR (€)
Nov. 30, 2022
USD ($)
Jul. 31, 2022
EUR (€)
Jul. 31, 2022
USD ($)
Dec. 31, 2022
EUR (€)
Dec. 31, 2022
EUR (€)
Dec. 31, 2024
EUR (€)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
EUR (€)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
EUR (€)
Dec. 31, 2021
EUR (€)
May 30, 2024
USD ($)
Sep. 29, 2023
USD ($)
Apr. 27, 2023
USD ($)
Mar. 13, 2023
USD ($)
$ / shares
Feb. 08, 2022
EUR (€)
Feb. 08, 2022
USD ($)
Oct. 01, 2021
EUR (€)
Disclosure of detailed information about business combination [line items]                                                    
Net cash flow on acquisition [1]                           € 1,901   € 2,535 [2]   € 987 [2]                
Net sales                           41,081   37,817 [3]   37,651 [3]                
Effect of the distribution of an exceptional supplementary dividend of 58% of the shares of EUROAPI to the equity holders of Sanofi [4]                                   793                
Investments accounted for using the equity method                       € 677 € 677 316   424   677                
Other gains, (losses) and litigation                           (470)   (196) [3]   (143) [3]                
Tax expense (income)                           (1,204)   (1,017) [3],[5]   (1,909) [3],[5]                
Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax [6]                           0   42 [2]   134 [2]                
Other intangible assets                       21,640 21,640 22,629   24,319   21,640                
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax [7]                           1,461   807 [2]   1,340 [2]                
Goodwill                       € 49,892 49,892 43,384   49,404   49,892                
Cash flows from (used in) investing activities, discontinued operations [8]                           € (109)   (1,250) [2]   42 [2]                
Enjaymo global rights | Major Collaboration Agreement                                                    
Disclosure of detailed information about business combination [line items]                                                    
Upfront payments for projects under collaboration agreements | $   $ 825.0                                                
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax € 768                                                  
Goodwill € 276                                                  
Regular milestone payments for projects under collaboration agreements | $   $ 250.0                                                
Assets Acquisition                                                    
Disclosure of detailed information about business combination [line items]                                                    
Contingent consideration recognised as of acquisition date | $                                       $ 300.0            
Net cash flow on acquisition | $                             $ 2,035.0                      
Consideration transferred, acquisition-date fair value | $                                       2,035.0            
Other intangible assets | $                                       $ 1,885.0            
Provision for decommissioning, restoration and rehabilitation costs                                                    
Disclosure of detailed information about business combination [line items]                                                    
Other provisions         € 14                                          
Regulatory compliance costs                                                    
Disclosure of detailed information about business combination [line items]                                                    
Other provisions         € 15                                          
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement                                                    
Disclosure of detailed information about business combination [line items]                                                    
Regular milestone payments for projects under collaboration agreements               € 96 $ 100.0                                  
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement | Major Collaboration Agreement                                                    
Disclosure of detailed information about business combination [line items]                                                    
Upfront payments for projects under collaboration agreements                   € 856 $ 900.0                              
AstraZeneca | Antibodies Collaboration agreement                                                    
Disclosure of detailed information about business combination [line items]                                                    
Commitments related to milestone payments for projects under collaboration agreements                               € 375                    
AstraZeneca | Antibodies Collaboration agreement | Major territories                                                    
Disclosure of detailed information about business combination [line items]                                                    
Percentage of profits arising from commercial operations                           5000.00% 5000.00%                      
EUROAPI                                                    
Disclosure of detailed information about business combination [line items]                                                    
Proportion of ownership interest in associate (in percent)                       30.10%   29.60% [9] 29.60% [9]                      
Ownership interest in subsidiary, minimum holding period         2 years                                          
Investments accounted for using the equity method                       € 413 413         413                
EUROAPI | EPIC BPIFrance                                                    
Disclosure of detailed information about business combination [line items]                                                    
Consideration transferred, valuation period             30 days                                      
EUROAPI                                                    
Disclosure of detailed information about business combination [line items]                                                    
Exceptional supplementary dividend proposed, percentage of share capital             58.00%                                      
Exceptional supplementary dividend, percentage of share capital         5800.00% 58.00%                                        
Special distribution, number of shares converted (in shares) | shares         23                                          
Special distribution, percentage of share capital distributed         57.88%                                          
Net sales                                     € 486              
Decrease through loss of control of subsidiary, net assets         € 1,227                                          
Decrease through loss of control of subsidiary, intangible assets and goodwill         € 164                                          
Weighted average share price (in EUR per share) | € / shares         € 14.58                                          
Net foreign exchange loss         € 35                                          
Other gains, (losses) and litigation         3                                          
Tax expense (income)         111                                          
Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax         € 101                         101                
EUROAPI | Manufacture and supply collaboration agreement                                                    
Disclosure of detailed information about business combination [line items]                                                    
Collaboration agreement, annual net sales target                                                   € 300
Collaboration agreement, commitment amount                       € 1,100 1,100         1,100                
EUROAPI | EPIC BPIFrance                                                    
Disclosure of detailed information about business combination [line items]                                                    
Percentage of voting equity interests divested       12.00%     12.00%                                      
Consideration transferred, maximum amount       € 150     € 150                                      
Opella Business                                                    
Disclosure of detailed information about business combination [line items]                                                    
Tax expense (income)                           € (122)                        
Financial interest in principal fully consolidated companies                           50.00% 50.00%                      
Valuation of Subsidiary                           € 16,000                        
Attributable to equity holders of Sanofi                                                     
Disclosure of detailed information about business combination [line items]                                                    
Effect of the distribution of an exceptional supplementary dividend of 58% of the shares of EUROAPI to the equity holders of Sanofi [4]                                   € 793                
Amunix Pharmaceuticals, Inc                                                    
Disclosure of detailed information about business combination [line items]                                                    
Cash transferred                                               € 970    
Commitments related to milestone payments, business combinations | $                                                 $ 225.0  
Contingent consideration recognised as of acquisition date                                               156    
Net cash flow on acquisition                         € 852                          
Identifiable intangible assets recognised as of acquisition date                                               493    
Consideration transferred, acquisition-date fair value                                               1,126    
Goodwill recognised as of acquisition date                                               € 609    
Provention Bio, Inc                                                    
Disclosure of detailed information about business combination [line items]                                                    
Cash transferred | $                                             $ 2,800.0      
Net cash flow on acquisition | $                                 $ 2,722.0                  
Purchase price per share (in euro/usd per share) | $ / shares                                             $ 25      
Financial interest in principal fully consolidated companies                       3.00%                            
Consideration transferred, acquisition-date fair value | $                                           $ 2,806.0        
Other intangible assets | $                                           $ 2,810.0        
QRIB Intermediate Holding                                                    
Disclosure of detailed information about business combination [line items]                                                    
Identifiable intangible assets recognised as of acquisition date     € 774                                              
Consideration transferred, acquisition-date fair value     1,343                                   $ 1,419.0          
Goodwill     484                                              
Cash flows from (used in) investing activities, discontinued operations     1,410                                              
Goodwill recognised as of acquisition date     € 484                                              
[1] This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For 2024,
it includes the net cash outflow relating to the acquisition of Inhibrx, Inc. (see Note D.1..1). For 2023, it includes the net cash outflow on the acquisitions of
Provention Bio (see Note D.1.). For 2022, it includes the net cash outflow on the acquisition of Amunix (see Note D.1.)
[2] Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations).
[3] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[4] This amount includes the valuation of the shares distributed as a dividend in kind, at a price of €14.58 per share, as of May 10, 2022 (see Note D.1.3).
[5] (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[6] For 2022, this line item includes the net cash inflows (before taxes) of €101 million on the divestment of EUROAPI (see Note D.1.).
[7] For 2024, this line item includes the sale of the Enjaymo global rights to Recordati for pre-tax proceeds of €768 million. For 2023 and 2022, this line item
mainly comprises disposals of assets and activities related to portfolio streamlining, and disposals of equity and debt instruments.
[8] For 2023, this line item includes the net cash outflow on the acquisition of QRIB (see Note D.1.)
[9] (a) The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (€2.88 as of December 31, 2024, and €5.73 as of December 31, 2023)